Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Is Expected To Reach USD 2.95 Billion By 2030

 San Francisco, 10 December 2025: The Report Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market (2025 - 2030) Size, Share & Trends Analysis Report By Device Type (Endovascular Devices, Surgical Devices), By Procedure, By End Use, By Region, And Segment Forecasts

The global aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 2.95 billion by 2030, growing at a CAGR of 5.5% from 2025 to 2030. Aorto-Iliac Occlusive Disease (AIOD) is a condition where the large arteries in the abdomen and pelvis, specifically the aorta and iliac arteries, become narrowed or blocked, reducing blood flow to the legs.

Key Market Trends & Insights

• North America dominated the aorto-iliac occlusive disease treatment market with the largest revenue share of 43.5% in 2024.
• The aorto-iliac occlusive disease treatment market in the U.S. accounted for the largest market revenue share in North America in 2024
• By end use, the hospitals segment led the market with the largest revenue share of 49.2% in 2024.
• By device type, the endovascular devices segment led the market with the largest revenue share of 87.5% in 2024.
• By procedure, the endovascular procedures segment led the market with the largest revenue share of 61.1% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 2.15 Billion
• 2030 Projected Market Size: USD 2.95 Billion
• CAGR (2025-2030): 5.5%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

The increasing prevalence of Peripheral Artery Disease (PAD) is one of the key factors driving the market's growth. According to the American Heart Association, Inc. article published in June 2023, Peripheral artery disease (PAD) affects an estimated 200 million people worldwide. It significantly contributes to developing Aorto-Iliac Occlusive Disease (AIOD). The growing prevalence of PAD, driven by factors such as aging populations, diabetes, and smoking, has increased the need for effective treatments for AIOD. This rising demand drives the adoption of minimally invasive procedures, including iliac artery stenting and endovascular therapies, which help restore proper blood flow and alleviate symptoms like leg pain and limited mobility.

Access Research Report of Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market @ https://www.grandviewresearch.com/industry-analysis/aorto-iliac-occlusive-disease-treatment-market-report

Key Aorto-Iliac Occlusive Disease Treatment Company Insights

Some of the key players operating in the industry include Boston Scientific Corporation, BD, and Abbott. The company’s key strategies include understanding the strengths and weaknesses of major market participants, anticipating future market trends, opportunities, and challenges, and making proactive decisions based on insights into emerging technologies and changing consumer preferences. For instance, Biotronik SE & Co KG and Getinge AB are some of the emerging players in the aorto-iliac occlusive disease (iliac disease) treatment industry.

Key Aorto-Iliac Occlusive Disease Treatment Companies:

The following are the leading companies in the aorto-iliac occlusive disease treatment market. These companies collectively hold the largest market share and dictate industry trends.

• Bentley InnoMed
• Scitech Medical
• Abbott
• Boston Scientific Corporation
• L. Gore & Associates, Inc.
• Medtronic
• Cook
• Terumo Corporation
• iVascular
• Getinge AB
• Biotronik SE & Co KG

Recent Developments

• In December 2024, Biotronikconcluded the BIO-OSCAR SOC trial, a prospective, multicenter, observational study evaluating current standard of care practices in treating peripheral artery disease (PAD). The study aimed to assess procedural outcomes and device use in endovascular treatments for atherosclerotic lesions, providing insights into real-world practices for managing PAD.
• In March 2024, Cook Medical entered into an exclusive distribution agreement with Getinge for the iCast covered stent system in the U.S. This collaboration aims to enhance the availability and distribution of the device, which is indicated for the treatment of iliac arterial occlusive disease.
• In January 2024, Zylox-Tonbridge Medical Technology Co., Ltd. has received marketing approval from the National Medical Products Administration (NMPA) for its ZYLOX® Peripheral Venous Stent System. This innovative device is designed to address lower limb and pelvic venous return disorders caused by iliac vein compression, such as May-Thurner Syndrome. 

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon